Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 09:30PM GMT
Release Date Price: $20.64 (+0.24%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

Hello, everyone, and thank you for joining us today at the Goldman Sachs Global Healthcare Conference. We are so pleased to be joined by Jean-Marc Bellemin and Friedrich Finckenstein from Iovance Biotherapeutics to give us an update on where things are and where things are headed through the rest of 2021.

Questions & Answers

Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

So to begin, let's start with the discussion of Iovance's core technology, which is a cell therapy technology called tumor-infiltrating lymphocytes or TILs. So at kind of first pass, can we start at a big picture level describing what TILs are and how they're employed as a therapeutic by Iovance?

Jean;Marc Bellemin
Iovance Biotherapeutics, Inc. - CFO & Principal Accounting Officer

Sure. Thank you, Madhu. I would like to give an introduction of Iovance, and again, thank you for hosting us at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot